China’s National Medical Products Administration (NMPA), the regulatory authority for medicines in China, has ceased importing, selling and using rivastigmine hydrogen tartrate capsules after finding issues with production at the company’s Indian manufacturing site during their remote inspection of the drug.
Rivastigmine hydrogen tartrate capsules are used for managing symptoms in people who have Alzheimer’s disease or cognitive impairment related to age and other causes.
Sun Pharmaceuticals Industries, which is India’s largest pharmaceutical company based on revenue, has yet to comment on this situation.
Response from China’s NMPA
After an inspection of an Indian manufacturing facility producing rivastigmine hydrogen tartrate capsules, the NMPA assessed production methods as unsatisfactory, leading them to ban all imports, sales and uses of these capsules.
Remote inspections have identified weaknesses in the facility’s procedures for contamination and the effectiveness of the facility’s quality management program, two of the pillars of GMP. All regulators in the world enforce GMP to protect quality of medicines and safety of patients.
The announcement from China revealed major issues about the facility’s contamination control procedures and how well the facility’s quality management department was able to perform its most important functions. These deficiencies were the basis for halting the facility until the corrective actions could be taken.
The Importance of This Decision
This decision is likely to have a significant impact on business and healthcare. Rivastigmine is currently used in China for treating patients with dementia from Alzheimer’s disease, which is becoming increasingly important as the number of elderly people increases throughout Asia. Having reliable access to dementia medications is critical to maintaining patient care, and any interruptions could have a direct impact on the continuity of treatment for patients using rivastigmine capsules.
For Sun Pharmaceutical Industries, which manufactures generic and specialty pharmaceutical products for global export, the imposition of regulatory bans in major markets could hinder both revenue growth and brand loyalty. The expanding Chinese marketplace will continue as a desirable place for foreign pharmaceutical manufacturers to expand their markets. The regulatory restrictions in China on products such as Central Nervous System (CNS) drugs (example – Rivastigmine), may hamper potential expansion plans.
China’s action follows the ongoing scrutiny that Sun Pharma has received relating to its FDA regulatory compliance efforts that are ongoing in the United States. In 2024, the FDA issued warning letters due to “serious violations” relating to Good Manufacturing Practices (GMP) at the very same facility in India where Rivastigmine is manufactured.
Warning letters from the FDA serve as an indicator that the FDA has major regulatory concerns that they expect manufacturers to resolve in reference to quality control or the potential for being subject to enforcement actions that may include import refusals and recalls of products. The lack of resolution of quality assurance concerns at a facility demonstrates, again, that the Facility has not corrected existing quality assurance issues.
According to the industry analysts, repeated regulatory flags in global markets could potentially lower the confidence of healthcare providers and purchasers in renewal contracts and access to various marketplaces. Sun Pharma has had a strong history of rectifying these issues with international compliance, however the latest ban clearly highlights that there is a continuing need for improved international compliance.
Market Response and Industry Response
Sun Pharma’s stock price has been trading very wildly over the last few days, reflecting significant investor uncertainty surrounding its reputation in the global manufacturing industry. The company has been experiencing higher than normal stock price volatility while analysts will continue to evaluate the future impact(s) of these events through quarterly financial reports.
Industry experts and analysts have indicated that due to recent scrutiny by regulatory agencies of manufacturers for compliance, the level of scrutiny of the compliance of manufacturers exporting medicines to multiple countries has increased substantially & further growth is expected by regulatory agencies to inspect/export to additional countries.
How to teach kids money lessons without making them money minded?
What Happens Next?
Sun Pharma now has to solve the regulatory concerns that the Chinese authorities have raised if it ever wants to start selling rivastigmine again there. This will likely involve better contaminant controls, substantial revamping of their quality management systems, and satisfactorily demonstrating compliance to the National Medical Products Association (NMPA).
The amount of time it takes to fix regulatory issues can range from weeks to months depending on how severe the issues are and how fast they can be fixed. Even if Sun Pharma takes corrective steps quickly, it appears as though China will continue to have very firm controls over the approval and supervision of all pharmaceutical products, therefore the continuation of rivastigmine in China will no doubt remain subject to strict verification and possibly new inspections.
For patients and their physicians, as well as the entire pharmaceutical community that is involved with the treatment of patients with Alzheimer’s disease, the immediate priority is to ensure that these drugs remain available to patients, and to determine when and if they will be again offered in the Chinese market.
